Hypercholesterolemia polygenic score modulates response to statin therapy

Helix presents research on how genetic risk for high LDL cholesterol impacts statin therapy response and cardiovascular event risk. Learn how polygenic scores could revolutionize personalized statin treatment strategies.

Attend this webinar to gain valuable insights that could revolutionize your approach to cardiovascular care. Dr. Liz Cirulli's research demonstrates how integrating genetic information into patient care can lead to more personalized and effective statin therapy. By understanding the relationship between genetic risk factors and statin response, you can learn to:

Key topics covered:

• Identify patients who may benefit from earlier statin intervention
• Optimize treatment based on individual genetic test results
• Potentially reduce cardiac events in identified high-risk patients
• Consider genetic factors in drug response and side effect profiles
• Using polygenic scores to stratify patients in clinical trials
• Real-world evidence can inform drug development and post-market studies

This webinar will provide invaluable information to help you advance personalized cardiovascular care and drive innovation in your field.

Speakers:

• Liz Cirulli Rogers, Associate Director Research, Helix
• Jay Shah, Associate Director, Lifesciences Product Marketing, Helix